These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

467 related items for PubMed ID: 2760167

  • 21. Prolactin-secreting macroadenomas in adolescents. Response to bromocriptine therapy.
    Tyson D, Reggiardo D, Sklar C, David R.
    Am J Dis Child; 1993 Oct; 147(10):1057-61. PubMed ID: 8213676
    [Abstract] [Full Text] [Related]

  • 22. In vitro effect of dopamine and L-dopa on prolactin and growth hormone release from human pituitary adenomas.
    Peillon F, Cesselin F, Bression D, Zygelman N, Brandi AM, Nousbaum A, Mauborgne A.
    J Clin Endocrinol Metab; 1979 Nov; 49(5):737-41. PubMed ID: 489713
    [Abstract] [Full Text] [Related]

  • 23. Five years follow-up of invasive prolactinomas with special reference to the control of cavernous sinus invasion.
    Wu ZB, Su ZP, Wu JS, Zheng WM, Zhuge QC, Zhong M.
    Pituitary; 2008 Nov; 11(1):63-70. PubMed ID: 17917811
    [Abstract] [Full Text] [Related]

  • 24. Abnormal dopamine sensitivity in some human prolactinomas.
    Pellegrini I, Costa R, Grisoli F, Jaquet P.
    Horm Res; 1989 Nov; 31(1-2):19-23. PubMed ID: 2722137
    [Abstract] [Full Text] [Related]

  • 25. Hormone secretion by cell culture of human GH-PRL secreting pituitary adenomas: effects of bromocriptine.
    Lei T, Bai X, Liu K, Hu W, Xue D, Jiang X.
    J Tongji Med Univ; 1998 Nov; 18(3):161-3. PubMed ID: 10806816
    [Abstract] [Full Text] [Related]

  • 26. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment.
    Colao A, Di Sarno A, Sarnacchiaro F, Ferone D, Di Renzo G, Merola B, Annunziato L, Lombardi G.
    J Clin Endocrinol Metab; 1997 Mar; 82(3):876-83. PubMed ID: 9062500
    [Abstract] [Full Text] [Related]

  • 27. The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas.
    Wang S, Wang A, Zhang Y, Zhu K, Wang X, Chen Y, Wu J.
    BMC Endocr Disord; 2021 Nov 23; 21(1):235. PubMed ID: 34814904
    [Abstract] [Full Text] [Related]

  • 28. Dopaminergic binding sites in human pituitary adenomas other than prolactinomas.
    Serri O, Marchisio AM, Collu R, Hardy J, Somma M.
    Horm Res; 1984 Nov 23; 19(2):97-102. PubMed ID: 6706294
    [Abstract] [Full Text] [Related]

  • 29. Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas.
    Fusco A, Gunz G, Jaquet P, Dufour H, Germanetti AL, Culler MD, Barlier A, Saveanu A.
    Eur J Endocrinol; 2008 May 23; 158(5):595-603. PubMed ID: 18426817
    [Abstract] [Full Text] [Related]

  • 30. Quantitative and functional expression of somatostatin receptor subtypes in human prolactinomas.
    Jaquet P, Ouafik L, Saveanu A, Gunz G, Fina F, Dufour H, Culler MD, Moreau JP, Enjalbert A.
    J Clin Endocrinol Metab; 1999 Sep 23; 84(9):3268-76. PubMed ID: 10487698
    [Abstract] [Full Text] [Related]

  • 31. Women with prolactinomas presented at the postmenopausal period.
    Shimon I, Bronstein MD, Shapiro J, Tsvetov G, Benbassat C, Barkan A.
    Endocrine; 2014 Dec 23; 47(3):889-94. PubMed ID: 24711223
    [Abstract] [Full Text] [Related]

  • 32. Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance.
    Delgrange E, Sassolas G, Perrin G, Jan M, Trouillas J.
    Acta Neurochir (Wien); 2005 Jul 23; 147(7):751-7; discussion 757-8. PubMed ID: 15971099
    [Abstract] [Full Text] [Related]

  • 33. Presence of high affinity dopamine receptors in estrone-induced, prolactin-secreting rat pituitary adenomas: a model for human prolactinomas.
    Eljarmak D, Marchisio AM, Lis M, Collu R.
    Horm Res; 1985 Jul 23; 21(2):107-16. PubMed ID: 3920132
    [Abstract] [Full Text] [Related]

  • 34. Dopaminergic receptors in human prolactin-secreting adenomas: a quantitative study.
    Bression D, Brandi AM, Martres MP, Nousbaum A, Cesselin F, Racadot J, Peillon F.
    J Clin Endocrinol Metab; 1980 Nov 23; 51(5):1037-44. PubMed ID: 7419680
    [Abstract] [Full Text] [Related]

  • 35. Primary medical therapy of micro- and macroprolactinomas in men.
    Pinzone JJ, Katznelson L, Danila DC, Pauler DK, Miller CS, Klibanski A.
    J Clin Endocrinol Metab; 2000 Sep 23; 85(9):3053-7. PubMed ID: 10999785
    [Abstract] [Full Text] [Related]

  • 36. Genes differentially expressed in prolactinomas responsive and resistant to dopamine agonists.
    Passos VQ, Fortes MA, Giannella-Neto D, Bronstein MD.
    Neuroendocrinology; 2009 Sep 23; 89(2):163-70. PubMed ID: 18791324
    [Abstract] [Full Text] [Related]

  • 37. Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up.
    Colao A, Loche S, Cappa M, Di Sarno A, Landi ML, Sarnacchiaro F, Facciolli G, Lombardi G.
    J Clin Endocrinol Metab; 1998 Aug 23; 83(8):2777-80. PubMed ID: 9709946
    [Abstract] [Full Text] [Related]

  • 38. PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes.
    Cristina C, Díaz-Torga GS, Goya RG, Kakar SS, Perez-Millán MI, Passos VQ, Giannella-Neto D, Bronstein MD, Becu-Villalobos D.
    Mol Cancer; 2007 Jan 12; 6():4. PubMed ID: 17222350
    [Abstract] [Full Text] [Related]

  • 39. Effects of chronic bromocriptine treatment of an estrone-induced, prolactin-secreting rat pituitary adenoma.
    Eljarmak D, Lis M, Cantin M, Carrière PD, Collu R.
    Horm Res; 1985 Jan 12; 21(3):160-7. PubMed ID: 3997065
    [Abstract] [Full Text] [Related]

  • 40. Somatostatin receptors, adenylate cyclase activity, and growth hormone (GH) response to octreotide in GH-secreting adenomas.
    Bertherat J, Chanson P, Dewailly D, Dupuy M, Jaquet P, Peillon F, Epelbaum J.
    J Clin Endocrinol Metab; 1993 Dec 12; 77(6):1577-83. PubMed ID: 7903312
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.